Compare Abeona Therapeutics Inc (ABEO) vs D R Horton Inc (DHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs D R Horton Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while D R Horton Inc trades at $148.65 (market cap $44.16B). The key difference: D R Horton Inc is far larger — about 118.3× Abeona Therapeutics Inc's market cap, and D R Horton Inc pays a 1.16% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DHI | |
|---|---|---|
Market Cap | $373.32M | $44.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $184.04 |
52-Week Low | $4.17 | $129.82 |
Enterprise Value | $228.22M | $48.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
D.R. Horton (DHI) trades at $155.72, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces headwinds from declining revenue and profit margins, with 2025 revenue dropping to $34.25B and net income falling to $3.59B. Recent earnings show mixed results with Q3 2025 missing expectations but Q4 2025 and Q1 2026 beating estimates. The company maintains strong operational cash flow of $3.42B despite a net cash outflow of $1.51B in 2025.
DHI presents a cautious opportunity with attractive valuation metrics (P/E 14.73, P/S 1.39) below sector averages, but faces significant housing market challenges. Analyst consensus leans neutral with 44% buy ratings and a $163.13 price target offering 4.8% upside. Key risks include housing market volatility, interest rate sensitivity, and competitive pressures in the homebuilding sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
